Structure-Activity Relationship of Azaindole-Based Glucokinase Activators

Journal of Medicinal Chemistry

Volumn 59, Issue 2, 2016, Pages 687-706

  Paczal, Attila ^a   Bálint, Balázs ^a   Wéber, Csaba ^a   Szabó, Zoltán B ^a   Ondi, Levente ^a   Theret, Isabelle ^b   De Ceuninck, Frédéric ^b   Bernard, Catherine ^b   Ktorza, Alain ^b   Perron Sierra, Francoise ^b   Kotschy, András ^a  

^a Servier Research Institute of Medicinal Chemistry   (Hungary)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL] BENZOIC ACID METHYL ESTER; 2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]BENZENEPHOSPHONIC ACID 2,2 DIMETHYLPROPANEDIOL ESTER; 2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]BENZONITRILE; 2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN2 YL)ETHYL]BENZENEPHOSPHONIC ACID DIETHYL ESTER; 2 CHLORO 4 [2 CYCLOPNETYL 1 (1H PYRROLO[2,3 B]PYRDIIN 2 YL)ETHYL]PHENOL; 2 CHLORO 4 [2 CYCLOPPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]BENZYL ALCOHOL; 2 METHYLSULFUNYL 5 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]CHLOROBENZENE; 2 [4 [2 CYCLOPNETYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]PHENYL] 5,5 DIMETHYL 1,3 DIOXAPHOSPHINANE 2 OXIDE; 3 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]CHLOROBENZENE; 4 [2 CYCLOPNETYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]BROMOBENZENE; 5 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL] 2 METHYLSULFONYL CHLOROBENZENE; AZAINDOLE; ENZYME ACTIVATOR; GLUCOKINASE; INDOLE DERIVATIVE; O (2 METHOXYISOPROPYL) 2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]PHENOL; O ISOPROPYL 2 CHLORO 4 [2 CYCLOPENTYL 1 (1H PYRROLO[2,3 B]PYRIDIN 2 YL)ETHYL]PHENOL; PIRAGLIATIN; UNCLASSIFIED DRUG; 7-AZAINDOLE DIMER; ANTIDIABETIC AGENT; GLUCOSE;

ALLOSTERISM; ARTICLE; ENZYME ACTIVITY; ENZYME STRUCTURE; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; LIVER CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; PRIMARY CELL CULTURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATORS; GLUCOKINASE; GLUCOSE; HEPATOCYTES; HYPOGLYCEMIC AGENTS; INDOLES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PRIMARY CELL CULTURE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84970934851     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01594     Document Type: Article

References (34)

1. Nolan, C. J.; Damm, P.; Prentki, M. Type 2 diabetes across generations: from pathophysiology to prevention and management Lancet 2011, 378, 169-181 10.1016/S0140-6736(11)60614-4
2. Matschinsky, F. M.; Magnuson, A. Eds. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. S. Karger: Basel, Switzerland, 2004.
3. For a review, see: Iynedjian, P. B. Molecular Physiology of Mammalian Glucokinase Cell. Mol. Life Sci. 2009, 66, 27-42 10.1007/s00018-008-8322-9
4. Matschinsky, F. M.; Zelent, B.; Doliba, N. M.; Kaestner, K. H.; Vanderkooi, J. M.; Grimsby, J.; Berthel, S. J.; Sarabu, R. Research and Development of Glucokinase Activators for Diabetes Therapy: Theoretical and Practical Aspects Handb. Exp. Pharmacol. 2011, 203, 357-401 10.1007/978-3-642-17214-4
5. Grimsby, J.; Sarabu, R.; Corbett, W. L.; Haynes, N. E.; Bizzarro, F. T.; Coffey, J. W.; Guertin, K. R.; Hilliard, D. W.; Kester, R. F.; Mahaney, P. E.; Marcus, L.; Qi, L.; Spence, C. L.; Tengi, J.; Magnuson, M. A.; Chu, C. A.; Dvorozniak, M. T.; Matschinsky, F. M.; Grippo, J. F. Allosteric activators of glucokinase: potential role in diabetes therapy Science 2003, 301, 370-373 10.1126/science.1084073
6. Hinklin, R. J.; Boyd, S. A.; Chicarelli, M. J.; Condroski, K. R.; DeWolf, W. E.; Lee, P. A.; Lee, W.; Singh, A.; Thomas, L.; Voegtli, W. C.; Williams, L.; Aicher, T. D. Identification of a new class of glucokinase activators through structure-based design J. Med. Chem. 2013, 56, 7669-7678 10.1021/jm401116k
7. Filipski, K. J.; Guzman-Perez, A.; Bian, J.; Perreault, C.; Aspnes, G. E.; Didiuk, M. T.; Dow, R. L.; Hank, R. F.; Jones, C. S.; Maguire, R. J.; Tu, M.; Zeng, D.; Liu, S.; Knafels, J. D.; Litchfield, J.; Atkinson, K.; Derksen, D. R.; Bourbonais, F.; Gajiwala, K. S.; Hickey, M.; Johnson, T. O.; Humphries, P. S.; Pfefferkorn, J. A. Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif Bioorg. Med. Chem. Lett. 2013, 23, 4571-4578 10.1016/j.bmcl.2013.06.036
8. Qian, Y.; Corbett, W. L.; Berthel, S. J.; Choi, D. S.; Dvorozniak, M. T.; Geng, W.; Gillespie, P.; Guertin, K. R.; Haynes, N.-E.; Kester, R. F.; Mennona, F. A.; Moore, D.; Racha, J.; Radinov, R.; Sarabu, R.; Scott, N. R.; Grimsby, J.; Mallalieu, N. L. Identification of RO4597014, a glucokinase activator studied in the clinic for the treatment of type 2 diabetes ACS Med. Chem. Lett. 2013, 4, 414-418 10.1021/ml400027y
9. Cheruvallath, Z. S.; Gwaltney, S. L., II; Sabat, M.; Tang, M.; Feng, J.; Wang, H.; Miura, J.; Guntupalli, P.; Jennings, A.; Hosfield, D.; Lee, B.; Wu, Y. Design, synthesis and SAR of novel glucokinase activators Bioorg. Med. Chem. Lett. 2013, 23, 2166-2171 10.1016/j.bmcl.2013.01.093
10. Park, K.; Lee, B. M.; Kim, Y. H.; Han, T.; Yi, W.; Lee, D. H.; Choi, H. H.; Chong, W.; Lee, C. H. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 2013, 23, 537-542 10.1016/j.bmcl.2012.11.018
11. Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the oxidation of aryl oxiranylmethanols and the synthesis of 2-aryl-N-thiazolyl-oxirane-2-carboxamides as glucokinase activators Tetrahedron Lett. 2012, 53, 4738-4742 10.1016/j.tetlet.2012.06.111
12. Bonn, P.; Brink, D. M.; Fagerhag, J.; Jurva, U.; Robb, G. R.; Schnecke, V.; Svensson Henriksson, A. S.; Waring, M. J.; Westerlund, C. The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold Bioorg. Med. Chem. Lett. 2012, 22, 7302-7305 10.1016/j.bmcl.2012.10.090
13. Pfefferkorn, J. A.; Tu, M.; Filipski, K. J.; Guzman-Perez, A.; Bian, J.; Aspnes, G. E.; Sammons, M. F.; Song, W.; Li, J.-C.; Jones, C. S.; Patel, L.; Rasmusson, T.; Zeng, D.; Karki, K.; Hamilton, M.; Hank, R.; Atkinson, K.; Litchfield, J.; Aiello, R.; Baker, L.; Barucci, N.; Bourassa, P.; Bourbounais, F.; Daquila, T.; Derksen, D. R.; MacDougall, M.; Robertson, A. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 2012, 22, 7100-7105 10.1016/j.bmcl.2012.09.082
14. Mao, W.; Ning, M.; Liu, Z.; Zhu, Q.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators Bioorg. Med. Chem. 2012, 20, 2982-2991 10.1016/j.bmc.2012.03.008
15. Sarabu, R.; Bizzarro, F. T.; Corbett, W. L.; Dvorozniak, M. T.; Geng, W.; Grippo, J. F.; Haynes, N.-E.; Hutchings, S.; Garofalo, L.; Guertin, K. R.; Hilliard, D. W.; Kabat, M.; Kester, R. F.; Ka, W.; Liang, Z.; Mahaney, P. E.; Marcus, L.; Matschinsky, F. M.; Moore, D.; Racha, J.; Radinov, R.; Ren, Y.; Qi, L.; Pignatello, M.; Spence, C. L.; Steele, T.; Tengi, J.; Grimsby, J. Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients J. Med. Chem. 2012, 55, 7021-7036 10.1021/jm3008689
16. Pfefferkorn, J. A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J. L.; Pettersen, J.; Minich, M. L.; Filipski, K. J.; Jones, C. S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B. D.; Bourassa, P.; Daquila, T.; Baker, L.; Barucci, N.; Robertson, A. S.; Bourbonais, F.; Derksen, D. R.; MacDougall, M.; Cabrera, O.; Chen, J.; Lapworth, A. L.; Landro, J. A.; Zavadoski, W. J.; Atkinson, K.; Haddish-Berhane, N.; Tan, B.; Yao, L.; Kosa, R. E.; Varma, M. V.; Feng, B.; Duignan, D. B.; El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; DaSilva-Jardine, P.; Sweet, L.; Liras, S.; Rolph, T. P. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus J. Med. Chem. 2012, 55, 1318-1333 10.1021/jm2014887
17. Lang, J. M.; Seifert, M. H.-J.; Wolf, K.; Aschenbrenner, A.; baumgartner, R.; Wieber, T.; Trentinaglia, V.; Blisse, M.; Tajima, N.; Yamashita, T.; Vitt, D.; Noda, H. Discovery and hit-to-lead optimization of novel allosteric glucokinase activators Bioorg. Med. Chem. Lett. 2011, 21, 5417-5422 10.1016/j.bmcl.2011.06.128
18. Pfefferkorn, J. A.; Guzman-Perez, A.; Oates, P. J.; Litchfield, J.; Aspnes, G.; Basak, A.; Benbow, J.; Berliner, M. A.; Bian, J.; Choi, C.; Freeman-Cook, K.; Corbett, J. W.; Didiuk, M.; Dunetz, J. R.; Filipski, K. J.; Hungerford, W. M.; Jones, C. S.; Karki, K.; Ling, A.; Li, J.-C.; Patel, L.; Perreault, C.; Risley, H.; Saenz, J.; Song, W.; Tu, M.; Aiello, R.; Atkinson, K.; Barucci, N.; Beebe, D.; Bourassa, P.; Bourbounais, F.; Brodeur, A. M.; Burbey, R.; Chen, J.; D'Aquila, T.; Derksen, D. R.; Haddish-Berhane, N.; Huang, C.; Landro, J.; Lapworth, A. L.; MacDougall, M.; Perregaux, D.; Pettersen, J.; Robertson, A.; Tan, B.; Treadway, J. L.; Liu, S.; Qiu, X.; Knafels, J.; Ammirati, M.; Song, X.; daSilva-Jardine, P.; Liras, S.; Sweet, L.; Rolph, T. P. Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus MedChemComm 2011, 2, 828-839 10.1039/c1md00116g
19. Litchfield, J.; Sharma, R.; Atkinson, K.; Filipski, K. J.; Wright, S. W.; Pfefferkorn, J. A.; Tan, B.; Kosa, R. E.; Stevens, B.; Tu, M.; Kalgutkar, A. S. Intrinsic electrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinase activators: role of glutathione-S-transferases and in vivo quantitation of a glutathione conjugate in rats Bioorg. Med. Chem. Lett. 2010, 20, 6262-6267 10.1016/j.bmcl.2010.08.095
20. Sidduri, A.; Grimsby, J. S.; Corbett, W. L.; Sarabu, R.; Grippo, J. F.; Lou, J.; Kester, R. F.; Dvorozniak, M.; Marcus, L.; Spence, C.; Racha, J. K.; Moore, D. J. 2,3-Disubstituted acrylamides as potent glucokinase activators Bioorg. Med. Chem. Lett. 2010, 20, 5673-5676 10.1016/j.bmcl.2010.08.029
21. Ishikawa, M.; Nonoshita, K.; Ogino, Y.; Nagae, Y.; Tsukahara, D.; Hosaka, H.; Maruki, H.; Ohyama, S.; Yoshimoto, R.; Sasaki, K.; Nagata, Y.; Eiki, J-i.; Nishimura, T. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators Bioorg. Med. Chem. Lett. 2009, 19, 4450-4454 10.1016/j.bmcl.2009.05.038
22. Li, F.; Zhu, Q.; Zhang, Y.; Feng, Y.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators Bioorg. Med. Chem. 2010, 18, 3875-3884 10.1016/j.bmc.2010.04.038
23. Haynes, N. E.; Corbett, W. L.; Bizzarro, F. T.; Guertin, K. R.; Hilliard, D. W.; Holland, G. W.; Kester, R. F.; Mahaney, P. E.; Qi, L.; Spence, C. L.; Tengi, J.; Dvorozniak, M. T.; Railkar, A.; Matschinsky, F. M.; Grippo, J. F.; Grimsby, J.; Sarabu, R. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675) J. Med. Chem. 2010, 53, 3618-3625 10.1021/jm100039a
24. Takahashi, K.; Hashimoto, N.; Nakama, C.; Kamata, K.; Sasaki, K.; Yoshimoto, R.; Ohyama, S.; Hosaka, H.; Maruki, H.; Nagata, Y.; Eiki, J-i.; Nishimura, T. The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators Bioorg. Med. Chem. 2009, 17, 7042-7051 10.1016/j.bmc.2009.05.037
25. Iino, T.; Sasaki, Y.; Bamba, M.; Mitsuya, M.; Ohno, A.; Kamata, K.; Hosaka, H.; Maruki, H.; Futamura, M.; Yoshimoto, R.; Ohyama, S.; Sasaki, K.; Chiba, M.; Ohtake, N.; Nagata, Y.; Eiki, J-i.; Nishimura, T. Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators Bioorg. Med. Chem. Lett. 2009, 19, 5531-5538 10.1016/j.bmcl.2009.08.064
26. Iino, T.; Hashimoto, N.; Sasaki, K.; Ohyama, S.; Yoshimoto, R.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J-i.; Nishimura, T. Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy Bioorg. Med. Chem. 2009, 17, 3800-3809 10.1016/j.bmc.2009.04.040
27. Mitsuya, M.; Kamata, K.; Bamba, M.; Watanabe, H.; Sasaki, Y.; Sasaki, K.; Ohyama, S.; Hosaka, H.; Nagata, Y.; Eiki, J-i.; Nishimura, T. Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators Bioorg. Med. Chem. Lett. 2009, 19, 2718-2721 10.1016/j.bmcl.2009.03.137
28. Bebernitz, G. R.; Beaulieu, V.; Dale, B. A.; Deacon, R.; Duttaroy, A.; Gao, J.; Grondine, M. S.; Gupta, R. C.; Kakmak, M.; Kavana, M.; Kirman, L. C.; Liang, J.; Maniara, W. M.; Munshi, S.; Nadkarni, S. S.; Schuster, H. F.; Stams, T.; St. Denny, I.; Taslimi, P. M.; Vash, B.; Caplan, S. L. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes J. Med. Chem. 2009, 52, 6142-6152 10.1021/jm900839k
29. Berthel, S. J.; Chen, L.; Corbett, W. L.; Feng, L. C.; Haynes, N.-E.; Kester, R. F.; So, S.-S.; Tilley, J. W. Azaindole Glucokinase Activators. US 20110144105, Chem. Abstr. 155: 93825.
30. Dave, B.; Deshpande, A.; Kurhade, S.; Kobal, B.; Bhuniya, D.; Palle, V. Fused Nitrogen Heterocyclic Compounds, Process Of Preparation And Uses Thereof. WO 2011080755, Chem. Abstr. 155: 182037.
31. De Ceuninck, F.; Kargar, C.; Ilic, C.; Caliez, A.; Rolin, J. O.; Umbdenstock, T.; Vinson, C.; Combettes, M.; de Fanti, B.; Harley, E.; Sadlo, M.; Lefèvre, A.-L.; Broux, O.; Wierzbicki, M.; Fourquez, J.-M.; Perron-Sierra, F.; Kotschy, A.; Ktorza, A. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans Br. J. Pharmacol. 2013, 168, 339-353 10.1111/j.1476-5381.2012.02184.x
32. De Ceuninck, F.; Kargar, C.; Charton, Y.; Goldstein, S.; Perron-Sierra, F.; Ilic, C.; Caliez, A.; Rolin, J. O.; Sadlo, M.; Harley, E.; Vinson, C.; Ktorza, A. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice Br. J. Pharmacol. 2013, 169, 999-1010 10.1111/bph.12172
33. Kamata, K.; Mitsuya, M.; Nishimura, T.; Eiki, J.; Nagata, Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase Structure 2004, 12, 429-438 10.1016/j.str.2004.02.005
34. Petit, P.; Antoine, M.; Ferry, G.; Boutin, J. A.; Lagarde, A.; Gluais, L.; Vincentelli, R.; Vuillard, L. The active conformation of human glucokinase is not altered by allosteric activators Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 929-935 10.1107/S0907444911036729